192 related articles for article (PubMed ID: 12952292)
41. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
Hall WA; Vallera DA
Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029
[TBL] [Abstract][Full Text] [Related]
42. Recombinant cytotoxins specific for cancer cells.
Debinski W
Ann N Y Acad Sci; 1999; 886():297-9. PubMed ID: 10667244
[No Abstract] [Full Text] [Related]
43. A soluble form of IL-13 receptor alpha 1 promotes IgG2a and IgG2b production by murine germinal center B cells.
Poudrier J; Graber P; Herren S; Gretener D; Elson G; Berney C; Gauchat JF; Kosco-Vilbois MH
J Immunol; 1999 Aug; 163(3):1153-61. PubMed ID: 10415009
[TBL] [Abstract][Full Text] [Related]
44. Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy.
Kawakami M; Kawakami K; Puri RK
J Neurooncol; 2003 Oct; 65(1):15-25. PubMed ID: 14649882
[TBL] [Abstract][Full Text] [Related]
45. Cancer gene therapy utilizing interleukin-13 receptor alpha2 chain.
Kawakami K
Curr Gene Ther; 2005 Apr; 5(2):213-23. PubMed ID: 15853729
[TBL] [Abstract][Full Text] [Related]
46. Interleukin-13 receptor alpha2 chain in human head and neck cancer serves as a unique diagnostic marker.
Kawakami M; Kawakami K; Kasperbauer JL; Hinkley LL; Tsukuda M; Strome SE; Puri RK
Clin Cancer Res; 2003 Dec; 9(17):6381-8. PubMed ID: 14695138
[TBL] [Abstract][Full Text] [Related]
47. IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells.
Rahaman SO; Sharma P; Harbor PC; Aman MJ; Vogelbaum MA; Haque SJ
Cancer Res; 2002 Feb; 62(4):1103-9. PubMed ID: 11861389
[TBL] [Abstract][Full Text] [Related]
48. Mutation and functional analysis of IL-13 receptors in human malignant glioma cells.
Kawakami M; Leland P; Kawakami K; Puri RK
Oncol Res; 2001; 12(11-12):459-67. PubMed ID: 11939409
[TBL] [Abstract][Full Text] [Related]
49. Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice.
Li C; Hall WA; Jin N; Todhunter DA; Panoskaltsis-Mortari A; Vallera DA
Protein Eng; 2002 May; 15(5):419-27. PubMed ID: 12034862
[TBL] [Abstract][Full Text] [Related]
50. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas.
Debinski W; Gibo DM; Hulet SW; Connor JR; Gillespie GY
Clin Cancer Res; 1999 May; 5(5):985-90. PubMed ID: 10353730
[TBL] [Abstract][Full Text] [Related]
51. Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy.
Kawakami M; Kawakami K; Stepensky VA; Maki RA; Robin H; Muller W; Husain SR; Puri RK
Clin Cancer Res; 2002 Nov; 8(11):3503-11. PubMed ID: 12429641
[TBL] [Abstract][Full Text] [Related]
52. The interleukin-13 receptor alpha2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway.
Kawakami K; Taguchi J; Murata T; Puri RK
Blood; 2001 May; 97(9):2673-9. PubMed ID: 11313257
[TBL] [Abstract][Full Text] [Related]
53. Interleukin 4 receptor-directed cytotoxin therapy for human head and neck squamous cell carcinoma in animal models.
Strome SE; Kawakami K; Alejandro D; Voss S; Kasperbauer JL; Salomao D; Chen L; Maki RA; Puri RK
Clin Cancer Res; 2002 Jan; 8(1):281-6. PubMed ID: 11801570
[TBL] [Abstract][Full Text] [Related]
54. Binding of interleukin-13 and interleukin-4 to the interleukin (IL)-4/IL-13 receptor of human synovial fibroblasts.
Lutz RA; Feng N; Moser R
J Recept Signal Transduct Res; 1999; 19(1-4):181-90. PubMed ID: 10071757
[TBL] [Abstract][Full Text] [Related]
55. Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi's sarcoma xenograft.
Husain SR; Puri RK
Blood; 2000 Jun; 95(11):3506-13. PubMed ID: 10828036
[TBL] [Abstract][Full Text] [Related]
56. The primary binding subunit of the human interleukin-4 receptor is also a component of the interleukin-13 receptor.
Zurawski SM; Chomarat P; Djossou O; Bidaud C; McKenzie AN; Miossec P; Banchereau J; Zurawski G
J Biol Chem; 1995 Jun; 270(23):13869-78. PubMed ID: 7775445
[TBL] [Abstract][Full Text] [Related]
57. Suppression of an IL-13 autocrine growth loop in a human Hodgkin/Reed-Sternberg tumor cell line by a novel IL-13 antagonist.
Oshima Y; Puri RK
Cell Immunol; 2001 Jul; 211(1):37-42. PubMed ID: 11585386
[TBL] [Abstract][Full Text] [Related]
58. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
Kahlon KS; Brown C; Cooper LJ; Raubitschek A; Forman SJ; Jensen MC
Cancer Res; 2004 Dec; 64(24):9160-6. PubMed ID: 15604287
[TBL] [Abstract][Full Text] [Related]
59. The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1.
Donaldson DD; Whitters MJ; Fitz LJ; Neben TY; Finnerty H; Henderson SL; O'Hara RM; Beier DR; Turner KJ; Wood CR; Collins M
J Immunol; 1998 Sep; 161(5):2317-24. PubMed ID: 9725226
[TBL] [Abstract][Full Text] [Related]
60. Characterization of a recombinant herpes simplex virus 1 designed to enter cells via the IL13Ralpha2 receptor of malignant glioma cells.
Zhou G; Roizman B
J Virol; 2005 May; 79(9):5272-7. PubMed ID: 15827141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
